Market Overview:
However, certain factors such as high costs associated with treatment and lack of awareness in some regions may restrain the growth of this market. On the basis of type, it can be divided into statins, MTP inhibitors (Lomitapide), PCSK9 inhibitors, and other drugs. MTP inhibitors (Lomitapide) are recommended for use only in adults with severe or very severe hFH who have not been able to lower their LDL cholesterol levels enough with other treatments.
Product Definition:
It can help identify risk factors and possible ways to prevent or treat the disease.
Statins:
Statin is a type of cholesterol-lowering medication. It's the most commonly prescribed drug worldwide and has been used to reduce cardiovascular risks in all patients, including those without known heart disease. Statins are widely available over the counter in various forms such as tablets, capsules and injections. They are also sold with prescription for home use which can be taken by people who cannot buy or do not want to buy them from a pharmacy.
MTP inhibitors (Lomitapide):
The normal function of LTPide (MTP inhibitors) is to prevent cholesterol from being absorbed by the cells. In this disorder, there is an inability of LTPide to inhibit lipase activity leading to excessive production of free fatty acids and a high risk for cardiovascular diseases in later life.
Application Insights:
The application segment is segregated into hospital, research institutes, and commercial.
In addition, a rise in awareness about early diagnosis through genetic testing is anticipated to fuel market growth over the forecast period. The growing incidence rate of CVDs coupled with rising healthcare expenditure globally will further augment demand for cholesterol-lowering therapies which will subsequently drive this market over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of this disease, increasing awareness about it, and availability of effective treatment in this region. Moreover, a higher number of patients opting for treatment is expected to drive growth during the forecast period. The introduction of new therapies will also contribute towards regional growth during the same period.
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Growing geriatric population
- Rising awareness about the benefits of early diagnosis and treatment
- Technological advancements in genetic testing and lipid management therapies
- Government initiatives to improve access to care and support research
Scope Of The Report
Report Attributes
Report Details
Report Title
Homozygous Familial Hypercholesterolemia Epidemiology Market Research Report
By Type
Statins, MTP inhibitors (Lomitapide), PCSK9 inhibitors, Other
By Application
Hospital, Research Institute, Commercial, Other
By Companies
Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, Amgen, Aegerion Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Homozygous Familial Hypercholesterolemia Epidemiology Market Report Segments:
The global Homozygous Familial Hypercholesterolemia Epidemiology market is segmented on the basis of:
Types
Statins, MTP inhibitors (Lomitapide), PCSK9 inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institute, Commercial, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Regeneron Pharmaceuticals
- Novartis
- LIB Therapeutics
- NeuroBo Pharmaceuticals
- Arrowhead Pharmaceuticals
- Amgen
- Aegerion Pharmaceutical
Highlights of The Homozygous Familial Hypercholesterolemia Epidemiology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Statins
- MTP inhibitors (Lomitapide)
- PCSK9 inhibitors
- Other
- By Application:
- Hospital
- Research Institute
- Commercial
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Homozygous Familial Hypercholesterolemia Epidemiology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The epidemiology of homozygous familial hypercholesterolemia (HFH) is not well understood. It is thought to be a rare disorder, affecting 1 in every 500 people. Most cases are inherited from parents who have the condition, but it can also occur spontaneously. HHV-6 appears to play a role in the development of HHFH, and there is evidence that treatment with antiviral medications may help reduce the risk of heart disease in people with HHFH.
Some of the major players in the homozygous familial hypercholesterolemia epidemiology market are Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, Amgen, Aegerion Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Homozygous Familial Hypercholesterolemia Epidemiology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Homozygous Familial Hypercholesterolemia Epidemiology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Homozygous Familial Hypercholesterolemia Epidemiology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size & Forecast, 2018-2028
4.5.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Size and Y-o-Y Growth
4.5.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Absolute $ Opportunity
Chapter 5 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
5.2.1 Statins
5.2.2 MTP inhibitors (Lomitapide)
5.2.3 PCSK9 inhibitors
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institute
6.2.3 Commercial
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Homozygous Familial Hypercholesterolemia Epidemiology Analysis and Forecast
9.1 Introduction
9.2 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
9.6.1 Statins
9.6.2 MTP inhibitors (Lomitapide)
9.6.3 PCSK9 inhibitors
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institute
9.10.3 Commercial
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Homozygous Familial Hypercholesterolemia Epidemiology Analysis and Forecast
10.1 Introduction
10.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
10.6.1 Statins
10.6.2 MTP inhibitors (Lomitapide)
10.6.3 PCSK9 inhibitors
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institute
10.10.3 Commercial
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Homozygous Familial Hypercholesterolemia Epidemiology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
11.6.1 Statins
11.6.2 MTP inhibitors (Lomitapide)
11.6.3 PCSK9 inhibitors
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institute
11.10.3 Commercial
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Analysis and Forecast
12.1 Introduction
12.2 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
12.6.1 Statins
12.6.2 MTP inhibitors (Lomitapide)
12.6.3 PCSK9 inhibitors
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institute
12.10.3 Commercial
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Homozygous Familial Hypercholesterolemia Epidemiology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Type
13.6.1 Statins
13.6.2 MTP inhibitors (Lomitapide)
13.6.3 PCSK9 inhibitors
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institute
13.10.3 Commercial
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Homozygous Familial Hypercholesterolemia Epidemiology Market: Competitive Dashboard
14.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Regeneron Pharmaceuticals
14.3.2 Novartis
14.3.3 LIB Therapeutics
14.3.4 NeuroBo Pharmaceuticals
14.3.5 Arrowhead Pharmaceuticals
14.3.6 Amgen
14.3.7 Aegerion Pharmaceutical
